<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9417">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02984345</url>
  </required_header>
  <id_info>
    <org_study_id>660065600</org_study_id>
    <nct_id>NCT02984345</nct_id>
  </id_info>
  <brief_title>Does the Ingestion of Mycoprotein Elicit an Optimal Anabolic Response in Resting and Exercised Skeletal Muscle?</brief_title>
  <acronym>ARM</acronym>
  <official_title>Does the Ingestion of Mycoprotein Elicit an Optimal Anabolic Response in Resting and Exercised Skeletal Muscle?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Exeter</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Exeter</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study will seek to quantify the muscle protein synthetic response to mycoprotein
      feeding, comparing it to milk protein as a gold standard and heavily researched positive
      control
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single Blind (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle fractional synthetic rate (muscle protein synthesis)</measure>
    <time_frame>7.5 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma amino acid concentration</measure>
    <time_frame>7.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum insulin concentration</measure>
    <time_frame>7.5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Molecular markers of muscle anabolism</measure>
    <time_frame>7.5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Mycoprotein beverage</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Milk protein beverage</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Mycoprotein beverage</intervention_name>
    <arm_group_label>Mycoprotein beverage</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Milk protein beverage</intervention_name>
    <arm_group_label>Milk protein beverage</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • BMI between 18 and 30 -

        Exclusion Criteria:

          -  Any diagnosed metabolic impairment (e.g. type 1 or 2 Diabetes)

          -  Any diagnosed cardiovascular disease or hypertension.

          -  Elevated blood pressure at the time of screening (e.g. blood pressure of
             ≥140/90mmHg).

          -  Chronic use of any prescribed or over the counter pharmaceuticals.

          -  A personal or family history of epilepsy, seizures or schizophrenia.

          -  Anyone with previous motor disorders.

          -  An allergy to mycoprotein / Quorn, penicillin, or milk.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alistair J Monteyne, MSc</last_name>
    <phone>+447803618368</phone>
    <email>am974@exeter.ac.uk</email>
  </overall_contact>
  <verification_date>December 2016</verification_date>
  <lastchanged_date>December 2, 2016</lastchanged_date>
  <firstreceived_date>December 2, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
